Want to see TSE:LCR full AI Analyst Report?
LCR Stock Chart & Stats
C$0.02
>-C$0.01(-20.00%)
At close: 4:00 PM EDT
C$0.02
>-C$0.01(-20.00%)
Day’s Range― - ―
52-Week RangeC$0.02 - C$0.07
Previous CloseN/A
Volume8.00K
Average Volume (3M)290.69K
Market Cap
C$2.18M
Enterprise ValueC$5.27
Total Cash (Recent Filing)C$33.82K
Total Debt (Recent Filing)C$1.10M
Price to Earnings (P/E)―
Beta0.80
Next Earnings
Aug 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding108,819,870
10 Day Avg. Volume583,757
30 Day Avg. Volume290,695
Financial Highlights & Ratios
PEG Ratio0.31
Price to Book (P/B)-9.40
Price to Sales (P/S)0.00
P/FCF Ratio-6.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
IP-driven R&D FocusNeonMind’s core business is early-stage therapeutic R&D around psychedelic compounds, creating intellectual property rather than relying on transactional sales. Durable IP assets and clinical-stage programs can compound value over multiple funding cycles and attract partnerships or licensing, supporting long-term strategic optionality for commercialization or collaboration.
Moderate Absolute DebtReported debt of roughly $1.1–$1.2M in 2025 is modest in absolute terms for a small biotech. Lower nominal debt reduces near-term interest and refinancing pressure, limiting fixed financial obligations and preserving options for equity financings or non-dilutive partnerships during continued R&D stages.
Improving Cash-flow TrendOperating and free cash flow remain negative, but documented improvement versus 2024 suggests better cost control or timing of expenditures. A trending improvement in cash burn is a durable operational signal that funding runway pressures may ease if the company sustains the trend or secures non-dilutive funding.
Bears Say
No Recurring RevenueThe company has effectively no recurring revenue across multiple years, meaning operations are entirely R&D funded rather than self-sustaining. Absence of revenue elevates dependency on external financing, increases dilution risk, and lengthens the timeline to achieve sustainable cash generation.
Persistent Net LossesContinuing multi-year operating and net losses (about -$1.8M in 2025) indicate the business has not yet demonstrated path to profitability. Ongoing losses consume cash and magnify capital needs, making the company vulnerable to funding shortfalls and constraining long-term strategic flexibility.
Negative Shareholders' EquityNegative shareholders' equity across reported periods signals solvency and balance-sheet weakness. This reduces borrowing capacity, increases financing costs, and raises potential for dilutive equity raises. Structurally, it undermines financial flexibility over the medium term and heightens funding risk.
NeonMind Biosciences Inc News
LCR FAQ
What was NeonMind Biosciences Inc’s price range in the past 12 months?
NeonMind Biosciences Inc lowest stock price was C$0.02 and its highest was C$0.07 in the past 12 months.
What is NeonMind Biosciences Inc’s market cap?
NeonMind Biosciences Inc’s market cap is C$2.18M.
When is NeonMind Biosciences Inc’s upcoming earnings report date?
NeonMind Biosciences Inc’s upcoming earnings report date is Aug 24, 2026 which is in 19 days.
How were NeonMind Biosciences Inc’s earnings last quarter?
Currently, no data Available
Is NeonMind Biosciences Inc overvalued?
According to Wall Street analysts NeonMind Biosciences Inc’s price is currently Overvalued.
Does NeonMind Biosciences Inc pay dividends?
NeonMind Biosciences Inc does not currently pay dividends.
What is NeonMind Biosciences Inc’s EPS estimate?
NeonMind Biosciences Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does NeonMind Biosciences Inc have?
NeonMind Biosciences Inc has 108,819,870 shares outstanding.
What happened to NeonMind Biosciences Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of NeonMind Biosciences Inc?
Currently, no hedge funds are holding shares in TSE:LCR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
NeonMind Biosciences Inc
Lancaster Resources Inc. focuses on acquiring, exploring, and advancing both mineral deposits and sustainable energy initiatives. A notable asset for the company is its exclusive right to acquire full ownership of the Alkali Flat lithium brine project, located in Lordsburg, New Mexico, in the United States. The firm's headquarters are situated in West Vancouver, Canada.